Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 650

1.

A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS.

Biomed Pharmacother. 2013 Jun;67(5):407-15. doi: 10.1016/j.biopha.2013.01.006. Epub 2013 Feb 16.

PMID:
23583193
2.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

3.

Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.

Jeon HS, Ahn MY, Park JH, Kim TH, Chun P, Kim WH, Kim J, Moon HR, Jung JH, Kim HS.

Int J Oncol. 2010 Aug;37(2):419-28.

PMID:
20596669
4.

Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.

Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C.

Anticancer Drugs. 2014 Aug;25(7):767-77. doi: 10.1097/CAD.0000000000000101.

PMID:
24686006
5.

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.

Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23.

PMID:
22134754
6.

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.

Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS.

Invest New Drugs. 2012 Aug;30(4):1434-42. doi: 10.1007/s10637-011-9718-1. Epub 2011 Jul 20.

PMID:
21773733
7.

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2006 Sep 1;12(17):5199-206.

8.

A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.

Yang L, Liang Q, Shen K, Ma L, An N, Deng W, Fei Z, Liu J.

Biomed Pharmacother. 2015 Apr;71:70-8. doi: 10.1016/j.biopha.2015.02.019. Epub 2015 Feb 26.

PMID:
25960218
9.

Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.

Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, Shen J, Shi YK.

Oncol Rep. 2013 Jul;30(1):499-505. doi: 10.3892/or.2013.2434. Epub 2013 Apr 29.

PMID:
23624828
10.

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.

PMID:
16343270
11.

Modulation of radiation response by histone deacetylase inhibition.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9.

PMID:
15850925
12.

The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.

Vallo S, Mani J, Stastny M, Makarević J, Juengel E, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.

Invest New Drugs. 2013 Apr;31(2):265-72. doi: 10.1007/s10637-012-9851-5. Epub 2012 Jul 17.

PMID:
22801803
14.

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.

PMID:
26314218
15.

A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.

De U, Kundu S, Patra N, Ahn MY, Ahn JH, Son JY, Yoon JH, Moon HR, Lee BM, Kim HS.

Biomol Ther (Seoul). 2015 Sep;23(5):434-41. doi: 10.4062/biomolther.2015.026. Epub 2015 Sep 1.

16.

Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.

Thakur VS, Gupta K, Gupta S.

Carcinogenesis. 2012 Feb;33(2):377-84. doi: 10.1093/carcin/bgr277. Epub 2011 Nov 23.

17.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
18.

Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.

Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD.

Mol Carcinog. 2000 Oct;29(2):92-102.

PMID:
11074606
19.

A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.

Patra N, De U, Kang JA, Kim JM, Ahn MY, Lee J, Jung JH, Chung HY, Moon HR, Kim HS.

Eur J Pharmacol. 2011 May 11;658(2-3):98-107. doi: 10.1016/j.ejphar.2011.02.015. Epub 2011 Mar 1.

PMID:
21376033
20.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.

PMID:
20838997

Supplemental Content

Support Center